ClinicalTrials.gg
CompletedNCT06005636Updated Oct 29, 2026

Post-stroke Delirium in Ischemic Stroke Patients

An observational study in Ischemic Stroke, sponsored by Jinan University Guangzhou. Completed at 1 site in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Jinan University Guangzhou · Observational

How we know

Updated Oct 29, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
985
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Enrollment
82nd of 188
985 · median 625
Started
2021
with 54 others
Observational
188 of 754
108 open now
Registered
379th of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 82nd largest by enrollment of the 188 observational ones that give a count, is one of 55 that started in 2021, is one of 188 observational ones, and was the 379th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This study is to investigate the predictors of post-stroke delirium, develop and validate a nomogram of post-stroke delirium in the ischemic stroke patients.

Read the detailed description

Introduction: Post-stroke delirium (PSD) is associated with unfavorable prognosis. Effectively identifying risk factors of PSD and predicting PSD is of essential.

Methods: This is a prospective, single-centered, cohort study.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

ischemic stroke patients were recruited from a Grade 3A hospital in Southern China.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged ≥18 years old;
  • ischemic stroke, confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) scans;
  • patients or their agencies agree to participate in this study.

Exclusion criteria

Exclusion Criteria:

  • brain dysfunction caused by non-vascular causes such as traumatic brain injury, brain tumor or brain tumor;
  • history of serious mental illness such as schizophrenia;
  • unable to cooperate to the assessment as deafness, blindness, aphasia, dysarthria;
  • be in coma [Glasgow Coma Scale (GCS)≤8 points] or sedation [Richmond Agitation Sedation Scale (RASS)\<-3 points], and do not ameliorate during study;
  • with incomplete data.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
985 participants (actual)
Patient registry
No

Groups and cohorts

  • with post-stroke delirium

    ischemic stroke patients with post-stroke delirium

    Diagnostic Test: Test delirium state

  • without post-stroke delirium

    ischemic stroke patients without post-stroke delirium

    Diagnostic Test: Test delirium state

Interventions

  • Diagnostic testTest delirium state

    use scale to test whether ischemic stroke patients have post-stroke delirium

06

What researchers measure

Primary outcomes

  1. Number of Participants with post-stroke delirium

    Time frame: The first week of admission

07

Study locations

1 site
  • the First Affiliated Hospital of Jinan University
    Guangzhou, Guangdong 510630, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Sep 2022, 12 months.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's 12 months is below that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Aug 22, 2023
StartActual
Sep 1, 2021
Primary completionActual
Sep 10, 2022
CompletionActual
Apr 27, 2023
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited, 2 added; 1 exclusion criterion edited, 4 added
What changed in the criteria
Inclusion criteria
  • Addedaged ≥18 years old;
  • Editedaged ≥18 years old;(2) ischemic stroke, confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) scans;(3) patients or their agencies agree to participate in this study.
  • Addedpatients or their agencies agree to participate in this study.
Exclusion criteria
  • Addedbrain dysfunction caused by non-vascular causes such as traumatic brain injury, brain tumor or metastatic brain tumor;
  • Addedhistory of serious mental illness such as schizophrenia;
  • Addedunable to cooperate to the assessment as deafness, blindness, aphasia, dysarthria;
  • Editedbrain dysfunction caused by non-vascular causes such as traumatic brain injury, brain tumor or metastatic brain tumor;(2) history of serious mental illness such as schizophrenia;(3) unable to cooperate to the assessment as deafness, blindness, aphasia, dysarthria;(4) be in coma [Glasgow Coma Scale (GCS)≤8 points] or sedation [Richmond Agitation Sedation Scale (RASS)<-3 points], and do not ameliorate during study;(5) with incomplete data.
  • Addedwith incomplete data.
Oct 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of Participants with post-stroke deliriumTime frame: The first week of admission
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Eligibility 1 inclusion criterion edited, 2 added; 1 exclusion criterion edited, 4 added
    What changed in the criteria
    Inclusion criteria
    • Addedaged ≥18 years old;
    • Editedaged ≥18 years old;(2) ischemic stroke, confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) scans;(3) patients or their agencies agree to participate in this study.
    • Addedpatients or their agencies agree to participate in this study.
    Exclusion criteria
    • Addedbrain dysfunction caused by non-vascular causes such as traumatic brain injury, brain tumor or metastatic brain tumor;
    • Addedhistory of serious mental illness such as schizophrenia;
    • Addedunable to cooperate to the assessment as deafness, blindness, aphasia, dysarthria;
    • Editedbrain dysfunction caused by non-vascular causes such as traumatic brain injury, brain tumor or metastatic brain tumor;(2) history of serious mental illness such as schizophrenia;(3) unable to cooperate to the assessment as deafness, blindness, aphasia, dysarthria;(4) be in coma [Glasgow Coma Scale (GCS)≤8 points] or sedation [Richmond Agitation Sedation Scale (RASS)<-3 points], and do not ameliorate during study;(5) with incomplete data.
    • Addedwith incomplete data.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of Participants with post-stroke deliriumTime frame: The first week of admission
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06005636
Lead sponsor
Jinan University Guangzhou
Collaborators
First Affiliated Hospital of Jinan University
Responsible party
Xiaoyan Cai (Ms, Jinan University Guangzhou) — Principal investigator
First posted
Aug 22, 2023
Start date
Sep 1, 2021
Primary completion
Sep 10, 2022
Completion
Apr 27, 2023
Last update
Oct 29, 2026

Study contacts

Fengxia Yan
principal investigator · Jinan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion